AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02394834 — intervention group
Intervention type: DRUG
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT02394834 — intervention group
Intervention type: DRUG
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT02802462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT
Description: sustained 60%VO 2max
Study NCT04558684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
Study NCT04558684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
Study NCT04558684 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiotherapy (5 Gy x 5 fractions)
Study NCT03276988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Period 1 GX-30, Period 2 THYROGEN®
Description: Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
Study NCT03276988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Period 1 THYROGEN®, Period 2 GX-30
Description: Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
Study NCT00743899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The aggressive group
Description: Stents were implanted in lesions with diameter stenosis >50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis >50% and RD ≥2.0 mm and \<2.25 mm.
Study NCT00743899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The conservative group
Description: Stenting was performed only in lesions with diameter stenosis >70% and reference diameter (RD) ≥2.25 mm
Study NCT02031211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
Study NCT02031211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
Study NCT02563951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 0.5mg
Study NCT02563951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 1.0mg
Study NCT02563951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 2.0mg
Study NCT02563951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril 1mg (IV injection)
Study NCT02563951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril 1mg (Tablet)
Study NCT02751099 — intervention group
Intervention type: OTHER
Intervention: transplanted patients
Description: bone biopsy, echocardiogram, blood samples
Study NCT03704311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
Study NCT03452228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Administered by Intravenous (IV)
Study NCT03452228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by Intravenous (IV)
Study NCT02699359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study NCT01833988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal Bionic Pancreas
Description: Automated blood glucose control via a closed-loop bionic pancreas device.
Study NCT01833988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
Study NCT03671629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced clinical pharmacist service
Description: The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
Study NCT01693094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,\& 6.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: 3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,\& 6.
Study NCT00299182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Study NCT04352946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pre-Exposure Prophylaxis
Description: HCQ PreP 400mg daily
Study NCT04352946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets 400mg daily
Study NCT04181320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Leg Ulcer Standard of Care with Granulox
Description: Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
Study NCT04997915 — intervention group
Intervention type: OTHER
Intervention: Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU
Description: Critical COVID-19 patients admitted to the ICU
Study NCT00904319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Power Training
Description: Aquatic power training program with an exercise specialist 2/week for 6 weeks.
Study NCT00713739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Study NCT00713739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Study NCT00713739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxazosin
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Study NCT00713739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
Study NCT02408562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i.c.v. infusion of sNN0031 by an Implanted infusion system
Description: I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
Study NCT02408562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: i.c.v. infusion of aCSF by an Implanted infusion system
Description: I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
Study NCT02693626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive cessation message
Description: Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
Study NCT02693626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not intensive cessation message
Description: Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
Study NCT03404960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib + Nivolumab
Description: Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
Study NCT00698984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BONISTEIN(R) bone blend
Description: 2 Capsules per day over a period of 6 months
Study NCT00698984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day over a period of 6 months
Study NCT04587544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion
Description: The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
Study NCT04185376 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
Study NCT00322101 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Radiation
Study NCT00322101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic transplantation
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV or orally
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or orally
Study NCT00322101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00322101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study NCT01041235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1123 (active drug = docetaxel)
Description: Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
Study NCT00786630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based case management
Description: Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
Study NCT00786630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management plus facilitated treatment alliance
Description: Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
Study NCT03164187 — intervention group
Intervention type: DRUG
Intervention: Diabeton 60 MR
Description: Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
Study NCT01992341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
Study NCT01992341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
Study NCT00322101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic transplantation
Study NCT00322101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00322101 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT03404960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib + Ipilimumab
Description: Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
Study NCT04135144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (printed materials)
Description: Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
Study NCT04135144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (video phone reminder)
Description: Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
Study NCT00322101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00322101 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT00944645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: niacin (+) laropiprant (Source 1)
Description: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
Study NCT03697967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine or prone position
Description: Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol.
Study NCT00322101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies